Objectives: The aim of this study was to characterize the mechanism of resistance to macrolides and streptogramins of a Streptococcus pneumoniae strain isolated from blood cultures in an 80-year-old patient suffering from severe pneumonia unsuccessfully treated with pristinamycin.
Introduction
Streptococcus pneumoniae is an important cause of communityacquired pneumonia. Penicillins are the treatment of choice of these infections and macrolides constitute an alternative in the case of intolerance to the drugs. However, increasing resistance to macrolides and related antibiotics [macrolides-lincosamidesstreptogramins (MLS)] among S. pneumoniae clinical isolates constitutes a worldwide problem. 1 In pneumococci, MLS resistance is mediated by two major mechanisms: target site modification and drug efflux. 1 Ribosomal alteration is mediated by a methyltransferase, encoded by the erm(B) gene [or rarely the erm(A) gene], that methylates the A2058 residue (Escherichia coli numbering) in domain V of the 23S rRNA and confers the so-called MLS B phenotype of cross-resistance among macrolides, lincosamides and streptogramins B. Active efflux is mediated by the mef(A) gene [formerly mef(E)] that codes for an efflux pump and is responsible for the so-called M phenotype characterized by unique resistance to 14-and 15-membered-ring macrolides (azithromycin, erythromycin, clarithromycin and roxithromycin). 1 In addition, mutations in 23S rRNA and the ribosomal proteins L4 and L22 (encoded by the rplD and rplV genes, respectively) have been infrequently described in pneumococci. 2 Resistance to macrolides can reach percentages exceeding 50% in certain countries and reduced susceptibility to erythromycin has become more frequent than reduced susceptibility to penicillin in Europe overall. 3 Telithromycin, a ketolide, and pristinamycin, an oral streptogramin, are molecules related to macrolides, which have demonstrated activity against pneumococci resistant to macrolides. 4 Pristinamycin is a combination of streptogramin A-type ( pristinamycin IIA) and streptogramin B-type ( pristinamycin IA) antibiotics. Although Erm methylases confer cross-resistance to macrolides, lincosamides and streptogramins B, synergism between the two streptogramin components is maintained, explaining the activity of the streptogramin combination. 2 Here, we report an S. pneumoniae isolate resistant to pristinamycin, an oral streptogramin, and mutated in ribosomal protein L22 isolated from blood cultures of a patient with lower respiratory tract infection unsuccessfully treated with pristinamycin.
Materials and methods

Bacterial strains and antimicrobial susceptibility testing
The strain of S. pneumoniae HM8989 was isolated from two blood cultures taken from an 80-year-old male patient suffering from severe pneumonia. He had been treated empirically with pristinamycin (3 g day) for 1 week for bronchial infection and was hospitalized at Henri Mondor hospital (Créteil, France) for persistent fever and increasing dyspnoea. The S. pneumoniae isolate was phenotypically identified and antimicrobial susceptibility was tested by the disc diffusion method. MICs of MLS antibiotics were determined by the agar dilution method on Mueller -Hinton agar medium, according to the recommendations of Comité de l'Antibiogramme de la Société Française de Microbiologie. 5 The reference strain S. pneumoniae ATCC 49619 was included as a control.
PCR and DNA sequence analysis
Bacterial genomic DNA was extracted using the QIAmp DNA Mini Kit (Qiagen, Courtaboeuf, France). Resistance genes erm(B) and mef(A) and portions of genes for domains V and II of the 23S rRNA (rrl) and genes for ribosomal proteins L4 (rplD) and L22 (rplV) were amplified using PCR with specific primers, as previously described. 6 PCR products were then sequenced in both directions using the ABI PRISM 3100 automatic sequencer (Applied Biosystems, Courtaboeuf, France). For identification of ribosomal mutations, sequences were compared with the genomic sequences of S. pneumoniae TIGR4 and R6 (GenBank accession numbers NC003098 and NC003028, respectively). Comparisons were done using the software available over the Internet at the National Center for Biotechnology Information web site (http:// www.ncbi.nlm.nih.gov/).
Results
Susceptibility to antimicrobial agents
By the disc diffusion method, the pneumococcal strain HM8989 was fully susceptible to all b-lactams tested with MICs of penicillin G, ampicillin and cefotaxime equal to 0.016, 0.016 and 0.008 mg/L, respectively. It also showed an intrinsic low-level resistance to aminoglycosides (streptomycin, kanamycin and gentamicin) and was susceptible to tetracyclines, chloramphenicol, rifampicin, co-trimoxazole, levofloxacin and vancomycin. In contrast, it exhibited a very uncommon profile of resistance to macrolides and related antibiotics with an intermediate susceptibility to erythromycin and pristinamycin. The strain remained fully susceptible to lincomycin. No D-shaped zone was visible when the disc of erythromycin was placed close to the disc of clindamycin.
MICs of MLS antibiotics are shown in Table 1 . MICs of erythromycin, clarithromycin, azithromycin, telithromycin and spiramycin for the strain HM8989 were 32-64-fold greater than those for the reference strain S. pneumoniae ATCC 49619. Despite the 32-fold increased MIC of telithromycin, the isolate remained categorized as susceptible to this antibiotic. MIC determination confirmed that the isolate was fully susceptible to lincosamides with MICs 2-4-fold lower than those for the reference strain. In addition, the isolate was resistant to the streptogramin combination quinupristin/dalfopristin with an 8-fold increase in the MIC of quinupristin, whereas the MIC of dalfopristin was the same. As expected, this strain was classified as 
Mutation in the rplV gene
No erm(B) methylase gene or mef(A) efflux gene could be detected by PCR with specific primers. No mutations were found in the rrl gene (domains II and V) or in the rplD gene for ribosomal protein L4. However, the strain displayed an 18 nucleotide tandem duplication at the 3 0 end of the rplV gene encoding ribosomal protein L22. This insertion corresponded to a six amino acid insertion ( 107 KRTAHI 108 ) tandemly duplicated ( Figure 1 ).
Discussion
Macrolide resistance in S. pneumoniae is mostly mediated by erm(B), a 23S rRNA methylase, and by mef(A), a gene encoding an efflux pump. 2 Since pristinamycin is still active against pneumococcal isolates displaying either mechanism, 2 this oral antibiotic represents an attractive option for the empirical treatment of respiratory tract infections. This report shows that resistance to streptogramins may emerge in clinical isolates through mutation in ribosomal protein L22 and can be associated with clinical failure of pristinamycin therapy. No early pneumococcal isolate from the patient was available. Therefore, we do not know whether the patient was infected by a strain already intermediate resistant to pristinamycin or whether strain HM8989 was a mutant selected under pristinamycin therapy. A few cases of clinical failure of pristinamycin for the treatment of lower respiratory tract infections have been reported. 7, 8 However, in these episodes, the strains remained susceptible to pristinamycin. Only two pneumococcal isolates from blood cultures have been reported in 1989, resistant to 16-membered macrolides and intermediate to pristinamycin. This resistance was shown to be due to an A2062C mutation in domain V of the 23S rRNA. 9 Since 2 Emergence of an L22 mutant during treatment with azithromycin of a fatal pneumococcal pneumonia emphasizes the clinical importance of this mutation as a resistance mechanism.
11 This isolate contained a tandem duplication 108 RTAHIT 109 with resistance to erythromycin, azithromycin and quinupristin/dalfopristin (MICs 2 -4 mg/L). The structure of the 50S ribosomal subunit containing a three-residue deletion mutant of L22 in Haloarcula marismortui showed a change in the L22 structure.
11 L22 mutations at the C-terminus could change the conformation of the b-hairpin and enlarge the exit tunnel for polypeptides. This suggested that L22 mutants are resistant to macrolides, because the lumen of the tunnel has become so large that it can no longer be obstructed efficiently by macrolides. However, as pointed out by Tu et al.,
12 the mechanism of L22 resistance is likely to be more complex, since macrolides bind to the tunnel entirely above the region affected by L22 mutations. The mechanism of resistance by mutation in L22 in S. pneumoniae has not been studied, but is probably similar. The tandem duplication that we found in the C-terminus of the L22 protein ( 107 KRTAHI
108
) was not exactly the same as those that were previously described ( 108 RTAHIT 109 ) among clinical isolates of macrolide-resistant S. pneumoniae.
2 However, these two close variations could be responsible for similar conformational changes in the riboprotein. In the literature, there is only one report of a macrolide-resistant pneumococcal mutant emerging during empirical treatment. Finally, L22 mutations did not affect the susceptibility to lincosamides but compromised the potency of the ketolides, with an increase in MIC of telithromycin from 0.008 to 0.25 mg/L. This report confirms the role of tandem duplications of ribosomal target protein L22 in MLS resistance in S. pneumoniae. This is the first report of emergence of a pneumococcal isolate resistant to streptogramins by mutation in ribosomal protein L22 during treatment with pristinamycin. Finally, it also highlights the risk of emergence of these mutants that present increased MICs of telithromycin. 
